Skip to main content

CELLINK

HardwareGothenburg, SwedenFounded 2016· One of 1733 Hardware companies tracked by AMPulse

Develops innovative 3D bioprinting systems including state-of-the-art bioprinters and bioinks used for printing human tissues and organs.

CEO / Founder
Anders Fogelberg
Stage
Public
Total Funding
Publicly Traded
Latest Round
IPO
Key Investors
Erik Penser Bank AB, Other institutional and strategic investors

Technology & Products

Key Products

Universal bioink, tissue-specific bioinks, 3D bioprinting systems.

Technological Advantage

Scalable automation solutions and integrated workflows that lower cost barriers and streamline bioprinting processes.

Patent position

CELLINK has filed 52 patent families, compared with 5 for Allevi, while Equipment's share fell from 77% to 57% and Applications' rose from 32% to 43%. AMPulse analysis

Filing momentum
16 families filed 2022–2024, 22 in 2019–2021
Focus, 2019–2021 → 2022–2024
Equipment 77% → 57%Applications 32% → 43%
Filed in
EP 38%US 27%WO 23%CN 13%
Named competitors, AM patent families
Allevi 5

52 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.

Differentiation

Value Proposition

Enables creation of complex, biomimetic tissues for drug discovery, personalized medicine, regenerative therapies, and cosmetic testing at lower costs with scalable, user-friendly technologies.

How They Differentiate

Combines scalable, cost-effective bioprinting hardware with an extensive portfolio of bioinks and a strong focus on automation and integrated workflows.

Market & Competition

Target Customers

Researchers, pharmaceutical companies, healthcare providers, and academic institutions

Industry Verticals

Biotechnology, Pharmaceuticals, Healthcare, Regenerative Medicine, Cosmetic Research

Competitors

Organovo Holdings; Allevi; Materialise

Growth & Milestones

Growth Metrics

Achieved rapid market valuation at IPO and significant revenue growth through strategic acquisitions and global expansion

Major Milestones

Released the world’s first universal bioink, IPO in 2017, Acquisition of Dispendix GmbH in 2018, Strategic acquisitions including Advanced BioMatrix, Key partnerships with industry leaders such as MedImmune

Notable Customers

Harvard University, Merck, Novartis, AstraZeneca, Johnson & Johnson, U.S. Army, Toyota, MIT, Takara Bio

https://bico.com

AM patents

AM-relevant patents linked to this company.

Patents
56
Granted
6
Families
52

Leading domains: process (56), equipment (41), application (19)

Filings by year: 2023: 3 · 2022: 13 · 2021: 6 · 2020: 8 · 2019: 9 · 2018: 6

  1. SILK FIBROIN AND RELATED USE FOR 3D BIOPRINTING2022180565 · WO
  2. 3D BIOPRINTER WITH CONTINUOUS WORKFLOW CAPABILITY20240157629 · US
  3. 3D BIOPRINTERS, A 3D BIOPRINTING TOOLHEAD AND A METHOD FOR 3D BIOPRINTING A CONSTRUCT04279275 · EP
  4. 3D Bioprinters20250001701 · US
  5. MODULAR NOZZLE FOR COAXIAL EXTRUSION04547471 · EP

Funding rounds

  • Series D$250.0M2022-02-16Lead: Whale Rock Capital Management
  • Series C$24.7M2021-03-23Lead: Lear Corporation

Equipment deals on record

Publicly disclosed purchases or installs only.

All equipment activity

Why this company matters

AMPulse analysis, not a company disclosure

CELLINK positions itself as a premier bioprinting company, combining scalable hardware with an extensive bioink portfolio to lower cost barriers in tissue engineering. Its proprietary bioink formulations and clean chamber technology aim to mimic natural cell growth environments, differentiating it from generalist 3D printing firms.

The company's core offering includes 3D bioprinting systems and a range of bioinks, from universal to tissue-specific formulations. These tools enable the fabrication of complex, biomimetic tissues for applications in drug discovery, personalized medicine, regenerative therapies, and cosmetic testing.

Customers include pharmaceutical companies such as Merck, Novartis, AstraZeneca, and Johnson & Johnson, as well as academic institutions like Harvard University and MIT. The U.S. Army and Toyota are also named users, indicating defense and industrial research interest. Products are reportedly used by more than 15 of the top 25 diagnostics companies.

CELLINK went public in 2017 and raised $315 million in total funding, with investors including Erik Penser Bank AB. Strategic acquisitions such as Dispendix GmbH and Advanced BioMatrix expanded its automation and biomaterials capabilities. Partnerships with Chalmers University of Technology and MedImmune support continued R&D. The company competes with Organovo and Allevi, but its integrated hardware-bioink workflow and automation focus provide a defensible position in the precision dispensing market.